Furthermore, the observation that S6K1−/− mice are characterized by small size and exhibit hypoinsulinemia suggests that targeting S6K1 for cancer therapy may be associated with significant side effects [60]. Here, RPS6KB1 is linked to Hypoinsulinemia.